Abstract
The aim of this review is to summarize present knowledge of genetic variation in cytochrome P450 1B1 (CYP1B1) and 2C9 (CYP2C9) genes and risk of tobacco-related cancer, female cancer, chronic obstructive pulmonary disease and ischemic vascular disease. The CYP1B1 and CYP2C9 enzymes metabolize polycyclic aromatic hydrocarbons found in tobacco smoke and thereby generate disease-causing metabolites suggested to be important in tobacco-related diseases. Furthermore, CYP1B1 also metabolizes estrogen while CYP2C9 metabolizes arachidonic acid, both creating metabolites potentially important in risk of female cancer or ischemic vascular disease. Genetic variation in genes coding for CYP1B1 and CYP2C9 enzymes have shown altered enzyme activity affecting levels of metabolites and thus potentially risk of disease. So far, however, findings have been inconsistent. Recently, large studies on the association between genetic variation in CYP1B1 and CYP2C9 and risk of disease with considerable statistical power rebutted the hypotheses that these genetic variants affect risk of tobacco-related cancer, female cancer, chronic obstructive pulmonary disease and ischemic vascular disease.
Keywords: Arachidonic acid, CYP1B1, CYP2C9, general population, polycyclic aromatic hydrocarbons, single nucleotide polymorphism, tobacco, 17β-estradiol, chronic obstructive pulmonary disease, ischemic vascular disease
Current Vascular Pharmacology
Title:Cytochrome P450 1B1 and 2C9 Genotypes and Risk of Ischemic Vascular Disease, Cancer, and Chronic Obstructive Pulmonary Disease
Volume: 10 Issue: 4
Author(s): Diljit Kaur-Knudsen, Stig E. Bojesen and Borge G. Nordestgaard
Affiliation:
Keywords: Arachidonic acid, CYP1B1, CYP2C9, general population, polycyclic aromatic hydrocarbons, single nucleotide polymorphism, tobacco, 17β-estradiol, chronic obstructive pulmonary disease, ischemic vascular disease
Abstract: The aim of this review is to summarize present knowledge of genetic variation in cytochrome P450 1B1 (CYP1B1) and 2C9 (CYP2C9) genes and risk of tobacco-related cancer, female cancer, chronic obstructive pulmonary disease and ischemic vascular disease. The CYP1B1 and CYP2C9 enzymes metabolize polycyclic aromatic hydrocarbons found in tobacco smoke and thereby generate disease-causing metabolites suggested to be important in tobacco-related diseases. Furthermore, CYP1B1 also metabolizes estrogen while CYP2C9 metabolizes arachidonic acid, both creating metabolites potentially important in risk of female cancer or ischemic vascular disease. Genetic variation in genes coding for CYP1B1 and CYP2C9 enzymes have shown altered enzyme activity affecting levels of metabolites and thus potentially risk of disease. So far, however, findings have been inconsistent. Recently, large studies on the association between genetic variation in CYP1B1 and CYP2C9 and risk of disease with considerable statistical power rebutted the hypotheses that these genetic variants affect risk of tobacco-related cancer, female cancer, chronic obstructive pulmonary disease and ischemic vascular disease.
Export Options
About this article
Cite this article as:
Kaur-Knudsen Diljit, E. Bojesen Stig and G. Nordestgaard Borge, Cytochrome P450 1B1 and 2C9 Genotypes and Risk of Ischemic Vascular Disease, Cancer, and Chronic Obstructive Pulmonary Disease, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812746
DOI https://dx.doi.org/10.2174/157016112800812746 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Elabela Peptide: An Emerging Target in Therapeutics
Current Drug Targets Perinatal Outcome in Pregnant Women with Heart Disease
New Emirates Medical Journal Tyrosol as a Neuroprotector: Strong Effects of a “Weak” Antioxidant
Current Neuropharmacology Formulation Development and Characterization of Guar Gum Microspheres for Colon Delivery
Nanoscience & Nanotechnology-Asia Retrospective Results on the Treatment of Chronic Hepatitis C with Different Interferon Regimes in a General Hospital
Current Drug Therapy A Critical Review of Bioactive Food Components, and of their Functional Mechanisms, Biological Effects and Health Outcomes
Current Pharmaceutical Design Surgical Ventricular Restoration: An Operation to Reverse Remodeling - Clinical Application (Part II) (Supplementry Table)
Current Cardiology Reviews Galectins-A Potential Target for Cardiovascular Therapy
Current Vascular Pharmacology Adiponectin: An Endothelium-Derived Vasoprotective Factor?
Current Vascular Pharmacology Diabetes without Manifest Cardiovascular Disease: A Novel Approach in Risk Stratification and Treatment Selection
Current Diabetes Reviews Antibody-drug Conjugates for Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Preeclampsia Prediction in Type 1 Diabetes and Diurnal Blood Pressure Methodology
Current Hypertension Reviews Mechanisms of Diabetic Dyslipidemia: Relevance for Atherogenesis
Current Vascular Pharmacology Effects of Some Indigenous Plants of North Karnataka (India) on Cardiovascular and Glucose Regulatory Systems in Alloxan-Induced Diabetic Rats
Cardiovascular & Hematological Agents in Medicinal Chemistry Co-morbidity of Covid-19 and Stenotrophomonas maltophilia in a Patient with Hodgkin's Lymphoma History from North of Iran
Infectious Disorders - Drug Targets sAPP Enhances the Transdifferentiation of Adult Bone Marrow Progenitor Cells to Neuronal Phenotypes
Current Alzheimer Research Triple-Valve Endocarditis in a Diabetic Patient: Case Report and Literature Review
Current Cardiology Reviews The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia
Current Neurovascular Research Pericytes Within A Pulmonary Neurovascular Unit in Coronavirus Disease 2019 Elicited Pathological Changes
Current Neurovascular Research N-Butyl Cyanoacrylate Embolization of a Peripheral Pulmonary Artery Aneurysm in a Patient with Patent Ductus Arteriosus
Current Cardiology Reviews